Macular atrophy at 5 years after photodynamic therapy for polypoidal choroidal vasculopathy
- 14 April 2022
- journal article
- research article
- Published by Springer Nature in Eye
- Vol. 37 (6) , 1067-1072
Abstract
Purpose To investigate predictors for macular atrophy (MA) involving the fovea after photodynamic therapy (PDT) followed by pro re nata (PRN) treatment for polypoidal choroidal vasculopathy (PCV). Methods This prospective observational study analysed treatment-naïve eyes with symptomatic PCV without MA at baseline which were followed up for 5 years. All eyes were initially treated with PDT, followed by a PRN regimen of anti-vascular endothelial growth factor (VEGF) therapy and/or PDT. We assigned eyes with and eyes without development of MA involving the fovea 5 years after the initial treatment into MA and non-MA groups, respectively. Baseline parameters and the number of treatments were compared between the two groups. Results Seventy-two eyes of 69 consecutive patients were included, and 29 eyes of 29 patients were analysed. Twelve (41%) and 17 (59%) eyes were assigned into the MA and non-MA groups, respectively. There were significant differences in subfoveal choroidal thickness (226.2 ± 47.8 μm vs. 278.8 ± 68.1 μm, P = 0.03) and number of anti-VEGF injections (13.7 ± 9.6 vs. 5.4 ± 5.6, P = 0.007) between the MA and non-MA groups, but not in the number of PDT sessions (P = 0.71). Best-corrected visual acuity at 5 years in the MA group was lower than in the non-MA group (P = 0.048). Conclusion Our long-term observation suggests that a thin subfoveal choroid at baseline and many followed anti-VEGF injections in a PRN regimen increase the risk for development of MA involving the fovea 5 years after PDT.Keywords
Funding Information
- MEXT | Japan Society for the Promotion of Science (18K09444)
This publication has 34 references indexed in Scilit:
- Understanding age-related macular degeneration (AMD): Relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complexMolecular Aspects of Medicine, 2012
- Expression and Role of VEGF in the Adult Retinal Pigment EpitheliumInvestigative Ophthalmology & Visual Science, 2011
- COMPARISON OF CHOROIDAL THICKNESS AMONG PATIENTS WITH HEALTHY EYES, EARLY AGE-RELATED MACULOPATHY, NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, CENTRAL SEROUS CHORIORETINOPATHY, AND POLYPOIDAL CHOROIDAL VASCULOPATHYRetina, 2011
- INTRAVITREAL RANIBIZUMAB WITH OR WITHOUT PHOTODYNAMIC THERAPY FOR THE TREATMENT OF SYMPTOMATIC POLYPOIDAL CHOROIDAL VASCULOPATHYRetina, 2011
- Choroidal Thickness in Polypoidal Choroidal Vasculopathy and Exudative Age-related Macular DegenerationOphthalmology, 2011
- One-Year Outcomes of Photodynamic Therapy in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Japanese PatientsOphthalmology, 2008
- Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathyOphthalmology, 2004
- Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathyBritish Journal of Ophthalmology, 2004
- Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyesGraefe's Archive for Clinical and Experimental Ophthalmology, 2002
- IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV)Retina, 1990